

# CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI) 2021

## HVTN ACTIVITIES

CROI 2021, taking place March 6-10, is geared toward researchers and clinical educators actively involved in the study and management of HIV, other retroviruses, and related medical conditions. This year, live and on-demand sessions will be available online to registered attendees during the conference. The following is a selection of talks and abstracts by HVTN-affiliated investigators at CROI (please note: this list may not reflect the entire HVTN program). **All times listed are in Eastern Standard Time.**

For more schedule details, visit the [CROI Agenda webpage](#).

### AGENDA

Sunday, March 7

#### N'GALY-MANN LECTURE

11:25 AM - 12:05 PM  
**Lessons from the Concurrent HIV/AIDS and COVID-19 Pandemics: A Two-Way Street**  
Anthony S. Fauci, National Institutes of Health, Bethesda, MD, USA

#### CONCURRENT TECHNICAL WORKSHOPS

12:20 PM - 2:20 PM  
**Design of Current and Future COVID-19 Vaccine Efficacy Trials**  
Holly Janes, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Monday, March 8

#### PLENARY SESSION

10:00 AM - 11:00 AM  
**Disparities in Health: From HIV to COVID-19 and Beyond**  
James Hildreth, Meharry Medical College, Nashville, TN, USA

Tuesday, March 9

#### PLENARY SESSION

10:00 AM - 11:00 AM  
**Sustained Delivery and Long-Acting Agents for Prevention of HIV**  
Linda-Gail Bekker, University of Cape Town, Cape Town, South Africa

#### CONCURRENT ORAL ABSTRACT SESSIONS

11:15 AM - 1:15 PM  
**New Weapons Against SARS-CoV-2 and HIV**  
Joseph J. Eron, University of North Carolina, Chapel Hill, NC, USA

#### COVID Epidemiology and Its Impact on HIV Care and Prevention

Anthony S. Fauci, National Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA

#### CONCURRENT INTERACTIVE SESSIONS

1:30 PM - 2:30 PM  
**T-Cell Immunity in SARS-CoV-2 Natural Infection and Following Vaccination**  
Julie McElrath, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

#### Pathological B-Cell activation During SARS-CoV-2 Infection

Ignacio Sanz, Emory University, Atlanta, GA, USA

#### From Daily Pills to Monthly Shots for HIV Prevention and Treatment: Can Efficacy Be Translated into Effectiveness?

Charles Flexner, The Johns Hopkins University, Baltimore, MD, USA  
Hyman Scott, San Francisco Department of Public Health, San Francisco, CA, USA

### ABSTRACT PRESENTATIONS


Science Spotlight Presentations:  
On Demand

#### Infusion Reactions in the Phase 2B Antibody Mediated Prevention (AMP) Studies

Simbarashe Takuva, Shelly Karuna, Michal Juraska, Erika Rudnicki, Srilatha Edupuganti, Maija Anderson, Robert De La Grecca, Martin R. Gaudinski, Margarita M. Gomez Lorenzo, David Burns, Myron S. Cohen, Lawrence Corey, Kathy Mngadi, Nyaradzo M. Mgodi, for AMP Study Teams

#### SARS-CoV-2 Neutralizing Antibody Responses in Convalescent Individuals in US and Peru

Shelly Karuna, Sue Li, Shannon Grant, April Randhawa, Meg Trahey, Jen Hanke, Lisa Sanders, Robert De La Grecca, Carissa Karg, Laura Polakowski, John Hural, Jessica Andriesen, Lawrence Corey, David Montefiori, for the HVTN 405/HPTN 1901 Study Team



**CROI**  
Conference on Retroviruses  
and Opportunistic Infections



**HIV VACCINE**  
TRIALS NETWORK

[hvtn.org](http://hvtn.org)